21st week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140142109 | ANTIFOLATE COMBINATIONS - The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments, the combinations are useful for treating certain conditions, such as rheumatoid arthritis. The invention also provides articles useful to provide the combinations in desirable dosage forms and combinations. The combinations further may be useful in the treatment of further conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis. | 2014-05-22 |
20140142110 | KINASE INHIBITOR - The invention is directed to a compound of formula (I): | 2014-05-22 |
20140142111 | Pyrazole Compounds for Controlling Invertebrate Pests - The present invention relates to pyrazole compounds of formulae I or II and the salts and N-oxides thereof, | 2014-05-22 |
20140142112 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 2014-05-22 |
20140142113 | METHOD OF TREATING INFLAMMATORY DISEASES USING ADENOSINE 2B RECEPTOR ANTAGONISTS - A method of treating inflammatory diseases with Adenosine 2B receptor antagonists in particular with xanthine derived inhibitors. The method involves supplying a therapeutically active amount of the compounds of FIG. | 2014-05-22 |
20140142114 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF - The present invention relates to novel anthelmintic compounds of formula (I) below: | 2014-05-22 |
20140142115 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds having structural Formula I: | 2014-05-22 |
20140142116 | Method of Treatment or Prophylaxis of Inflammatory Pain - A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT | 2014-05-22 |
20140142117 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 2014-05-22 |
20140142118 | CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY - A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker. | 2014-05-22 |
20140142119 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 2014-05-22 |
20140142120 | METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2 - The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity. | 2014-05-22 |
20140142121 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS - Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation. | 2014-05-22 |
20140142122 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL - Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies. | 2014-05-22 |
20140142123 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-05-22 |
20140142124 | Compositions for Topical Application Having Androgenic Actions - A composition comprising at least one physiologically tolerated film-forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I | 2014-05-22 |
20140142125 | Synthetic Rigidin Analogues as Anticancer Agents, Salts, Solvates and Prodrugs Thereof, and Method of Producing Same - A compound having the Formula I as follows: | 2014-05-22 |
20140142126 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-05-22 |
20140142127 | Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils - Disclosed are stable formulations of omega-3 oils and HMG-CoA reductase inhibitors. The invention comprises an omega-3 oil, a salt form of an HMG-CoA reductase inhibitor, and a salt. These compositions are stable in liquid form useful for combination therapy. | 2014-05-22 |
20140142128 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. | 2014-05-22 |
20140142129 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. | 2014-05-22 |
20140142130 | COMBINATIONS OF PYRIMETHANIL AND MONOTERPENES - The present invention relates to combinations of pyrimethanil, or a salt thereof, and a monoterpene, or a salt thereof, which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of pyrimethanil, or a salt thereof, together with a monoterpene selected from thymol and β-thujaplicin in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like. | 2014-05-22 |
20140142131 | LONG-ACTING INJECTABLE ANALGESIC FORMULATIONS FOR ANIMALS - Long acting injectable analgesic formulations and methods for providing long lasting pain relief in animals are disclosed. | 2014-05-22 |
20140142133 | MODULATION OF CELL BARRIER DYSFUNCTION - The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., sepsis. Methods of reducing at least a symptom of sepsis and the risk of developing sepsis are also provided. | 2014-05-22 |
20140142134 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM - Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as | 2014-05-22 |
20140142135 | 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS - The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, | 2014-05-22 |
20140142136 | Enhanced Erythropoiesis and Iron Metabolism - The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease. | 2014-05-22 |
20140142137 | HIV INTEGRASE INHIBITORS - Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof. | 2014-05-22 |
20140142138 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. | 2014-05-22 |
20140142139 | DIHYDROPYRAZOLE GPR40 MODULATORS - The present invention provides compounds of Formula (I): | 2014-05-22 |
20140142140 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS - An anti-epileptic agent for use in the treatment of a neurological disorder other than epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms. | 2014-05-22 |
20140142141 | DEUTERIUM-ENRICHED LENALIDOMIDE - The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2014-05-22 |
20140142142 | SPOT-ON PESTICIDE COMPOSITION - A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area. | 2014-05-22 |
20140142143 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 2014-05-22 |
20140142144 | Oxazolidinone Compounds and Their Uses in Preparation of Antibiotics - The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant | 2014-05-22 |
20140142145 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR - The present invention is directed to a combination comprising a dipeptidylpeptidase-IV (DPP-IV) inhibitor in free or pharmaceutically acceptable form, and at least one further antidiabetic compound or the pharmaceutically acceptable salt of such a compound, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV, such as impaired glucose tolerance, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis, and preferably diabetes, especially type 2 diabetes mellitus. | 2014-05-22 |
20140142146 | COMPOUNDS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 2014-05-22 |
20140142147 | Carbocyanines for G-Quadruplex DNA Stabilization and Telomerase Inhibition - Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer. | 2014-05-22 |
20140142148 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems. | 2014-05-22 |
20140142149 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY - Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases. | 2014-05-22 |
20140142150 | TREATING NEUROPSYCHIATRIC DISORDERS - The specification provides methods of treating a subject suffering from a neuropsychiatric disorder and methods of determining whether a subject is suffering from or at risk for developing a neuropsychiatric disorder or likely to respond to a specified treatment method. | 2014-05-22 |
20140142151 | ALLANTOIN-CONTAINING SKIN CREAM - An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant. | 2014-05-22 |
20140142152 | METHODS AND COMPOUNDS FOR TREATING CANCER - The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject. | 2014-05-22 |
20140142153 | BENDAMUSTINE FORMULATIONS - Aspects of the present appliction relate to pharmaceutical formulations comprising bendamustine or its pharmaceutically acceptable salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, polymorphs, and mixtures therof, suitable for phamaceutical use. Aspects further provide methods of producing stable bendamustine compositions. | 2014-05-22 |
20140142154 | ANTI-FUNGAL AGENT - An antifungal agent against a fungus of the genus | 2014-05-22 |
20140142155 | METHOD OF TREATING THROMBOCYTOPENIA - Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human. | 2014-05-22 |
20140142156 | Non-Lactone Carbocyclic and Heterocyclic Antagonists and Agonists of Bacterial Quorum Sensing - Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial. | 2014-05-22 |
20140142157 | EXTRACT OF ASPLENIUM NIDUS L. - An extract of | 2014-05-22 |
20140142158 | STABLE MICRONISED MONOCLINIC FORM OF ASENAPINE MALEATE AND ITS SYNTHESIS - A stable micronised monoclinic form of asenapine maleate is described, which comprises 5% by weight or less of orthorhombic form or any other crystalline form of asenapine maleate, wherein the asenapine maleate has a particle size distribution characterised by a d90 equal to or below 40 μm. Processes for preparing the stable micronised monoclinic form of asenapine maleate are also described. Formula (I). | 2014-05-22 |
20140142159 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS - The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) | 2014-05-22 |
20140142160 | Polycomb-associated Non-Coding RNAs - This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs. | 2014-05-22 |
20140142161 | RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES - The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency). | 2014-05-22 |
20140142162 | Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes - The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides. | 2014-05-22 |
20140142163 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field - The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis. | 2014-05-22 |
20140142164 | DENSOVIRUS-DERIVED VECTOR FOR GENE TRANSFER IN INSECTS - The present invention relates to a vector including: (i) an inverted terminal repeat (ITR) nucleotide sequence at the 5′ position; (ii) a nucleotide sequence functionally bonded to a promoter at the central position, said nucleotide sequence coding for a toxin; and (iii) an inverted terminal repeat (ITR) nucleotide sequence at the 3′ position, wherein said vector does not include any viral nucleotide sequences of | 2014-05-22 |
20140142165 | THERAPEUTIC PARTICLES SUITABLE FOR PARENTERAL ADMINISTRATION AND METHODS OF MAKING AND USING SAME - Disclosed herein are therapeutic compositions for treating and preventing diseases such as neointimal hyperplasia (NIH), where the compositions comprise a therapeutic particle that has a localized association with a blood vessel and a therapeutic agent, such as an anti-NIH agent. Methods of use of the therapeutic compositions are also disclosed. | 2014-05-22 |
20140142166 | COMPOSITION AND METHOD FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS - Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed. | 2014-05-22 |
20140142167 | Micellar Preparation Containing Sparingly Water-Soluble Anticancer Agent And Novel Block Copolymer - Micellar preparation in which the solubility of a sparingly water-soluble anticancer agent has been heightened and which after intravenous administration, enables a high blood concentration to be maintained. The preparation has high medicinal activity and/or reduced side effects, and is formed from a block copolymer represented by formula (1): | 2014-05-22 |
20140142168 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HORMONE-REFRACTORY PROSTATE CANCERS - The present invention relates to a combination of a curcuminoid and a taxane for use in the treatment of a hormone-refractory prostate cancer (HRPC) in a patient in need thereof. | 2014-05-22 |
20140142169 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION - The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties. | 2014-05-22 |
20140142170 | COMPOSITION AND METHOD FOR INFLUENCING ENERGY METABOLISM AND TREATING METABOLIC AND OTHER DISORDERS - A composition and method for influencing energy metabolism and treating metabolic and other disorders is provided. A terpenoid lactone that is a selective activator of SIRT1 is generally in the form of a terpenoid dilactone having a 5-alkeny-loxy-furan-2- one group, such as strigolactone, GR 24, or another strigolactone analog, and is used as a therapeutic agent in a method for influencing energy metabolism and treating metabolic and other disorders. The terpenoid lactone may be administered as an individual agent or combined with a second compound such as a flavonoid, chalconoid, tannin, or nicotinamide inhibition antagonist. | 2014-05-22 |
20140142171 | ANTI-GLYCATION AGENT COMPRISING A GARCINIA KOLA EXTRACT OR FRACTION - An anti-glycation agent includes a | 2014-05-22 |
20140142172 | Medical Food for Cognitive Decline - Nutraceutical formulations that improve cognitive function in adults diagnosed with neurodegenerative disease are provided, which comprise a combination of fisetin and DHA. | 2014-05-22 |
20140142173 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A NEURODEGENERATIVE DISEASE, COMPRISING A DAPHNE GENKWA EXTRACT OR A COMPOUND ISOLATED THEREFROM - The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a | 2014-05-22 |
20140142174 | DARUNAVIR FORMULATIONS - This invention relates to solid oral dosage forms of the HIV inhibitor darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof. | 2014-05-22 |
20140142175 | ANHYDROUS COSMETIC COMPOSITIONS CONTAINING ASCORBIC ACID - The disclosure relates to cosmetic compositions comprising ascorbic acid, at least two polyols, and a copolymer, wherein the composition is essentially anhydrous. The cosmetic compositions are particularly suitable for use on the face of a consumer, for example, as a facial mask. The disclosure also provides methods for improving the appearance of skin, for delivering ascorbic acid to the skin, and/or for reducing the effects and appearance of aging using the cosmetic compositions described herein. | 2014-05-22 |
20140142176 | CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF - Provided herein are novel carbon-monoxide releasing molecules (CO-RMs) of the Formula (I): and esters, amides, salts, solvates and hydrates thereof; wherein R | 2014-05-22 |
20140142177 | TOPICAL ORGANIC ACID SALT COMPOSITIONS SUITABLE FOR TREATING INFECTIONS - A non-toxic, topical antifungal composition and use of the composition for treating infections comprising a combination of at least three or more low molecular weight, hydrophilic organic acid salts and/or derivatives exhibiting a synergistic enhancement, dissolved in a carrier, wherein the low molecular weight organic acid salts are selected from the group consisting of saturated and unsaturated, acyclic, branched and unbranched aliphatic carboxylic acids wherein the longest carbon chain has eight carbons, and aromatic carboxylic acids containing less than ten carbon atoms; the carrier comprises one or more non-aqueous, non-volatile polyhydric solvents; and wherein the combination of low molecular weight, hydrophilic organic acid salts or derivatives comprises between about 0.5% to about 50 by weight of the composition, and no single acid salt or derivative comprises more than about 75% by weight of the total acid content. | 2014-05-22 |
20140142178 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA - Novel compounds of Formula I are provided: | 2014-05-22 |
20140142179 | 4-HYDROXYBUTYRIC ACID ANALOGS - This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate. | 2014-05-22 |
20140142180 | METHODS OF TREATING TUMORS HAVING ELEVATED MCT1 EXPRESSION - In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to 3-bromopyruvate (3-BrPA) are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with 3-BrPA are provided. In some aspects, compositions useful for subjects with cancers that express increased levels of MCT1 are provided. In some aspects, methods of treating subjects with cancers that express increased levels of MCT1 are provided. In some aspects, methods of identifying anti-tumor agents the efficacy of which is at least in part dependent on transporter-mediated uptake are provided. | 2014-05-22 |
20140142181 | TREATING AND INHIBITING RECURRENCE OF MUSCLE CRAMPS - A method of topical application of a creatine composition for treating and/or inhibiting recurrence of muscle cramps/spasms as well as muscle pain and/or stiffness associated therewith. | 2014-05-22 |
20140142182 | Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid - An aqueous liquid composition comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or hydrate; (b) a non-ionic surfactant; and (c) a preservative; wherein at least 90 percent of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt or hydrate remains in the composition after storage at 60° C., for 4 weeks. The composition can satisfy the preservative efficacy of US Pharmacopeia 35 (2012). The composition is useful for the treatment of ocular or nasal inflammation of diverse etiology. | 2014-05-22 |
20140142183 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 2014-05-22 |
20140142184 | TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 2014-05-22 |
20140142185 | 3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or its pharmaceutically acceptable salts. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 2014-05-22 |
20140142186 | METHODS OF ADMINISTERING AND EVALUATING NITROGEN SCAVENGING DRUGS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY - The present disclosure provides methods for treating hepatic encephalopathy (HE) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with HE. | 2014-05-22 |
20140142187 | Pharmaceutical Suspension Composition - An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously. | 2014-05-22 |
20140142188 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM - Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part. | 2014-05-22 |
20140142189 | METHIONINE ANALOGS AND METHODS OF USING SAME - Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages. | 2014-05-22 |
20140142190 | BIODEGRADABLE SINGLE-PHASE COHESIVE HYDROGELS - Biodegradable single-phase cohesive hydrogels useful, e.g., for the formulation of viscosupplementation compositions or compositions for filling wrinkles, contain a homogeneous blend of x polymers, which may be identical or different, crosslinked prior to the interpenetration thereof by mixing in the form of a single-phase hydrogel, wherein such crosslinked polymers are insoluble in water and miscible with one another, and x ranges from 2 to 5; in one embodiment, the hydrogels are such that the x polymers have identical or different degrees of crosslinking, at least one of the x polymers having a degree of crosslinking x1 and at least one of the x polymers having a degree of crosslinking x2, with x1 being greater than or equal to x2. | 2014-05-22 |
20140142191 | PRODUCTION OF THERMOREVERSIBLE HYDROGELS FOR THERAPEUTIC APPLICATIONS - A method is disclosed for production of a sterile thermoreversible hydrogel characterized by a known temperature T | 2014-05-22 |
20140142192 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators - The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y. | 2014-05-22 |
20140142193 | Stabilized Compositions Of Alkylating Agents And Methods Of Using Same - A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol. | 2014-05-22 |
20140142194 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES - The present invention provides methods and compositions for treating neurodegenerative diseases by cyclohexenone compounds. | 2014-05-22 |
20140142196 | METHOD OF KILLING BEDBUG EGGS - The present invention relates to a method of pre-rinsing laundry and treating other surfaces employing a composition that can kill bedbug eggs. The composition includes a fatty alcohol and an alcohol ethoxylate. | 2014-05-22 |
20140142197 | DISINFECTANT FORMULATION - An aqueous disinfectant formulation comprising at least one phenolic compound of natural origin; a surfactant sufficient to form a solution or dispersion of the essential oil in an aqueous carrier; a solvent, and sufficient water to make 100 weight percent is described herein. | 2014-05-22 |
20140142198 | CROSS-LINKED POLY-E-LYSINE NON-PARTICULATE SUPPORT - The invention provides a non-particulate cross-linked poly-ε-lysine polymer. The poly-ε-lysine and cross linker are linked by amide bonds and may the cross linker has at least two functional groups capable of reacting with an alpha carbon amine of poly-ε-lysine. The polymer is suitably insoluble in water and other solvents and is provided in macro form for example a sheet, article or fibre. The macro form polymer is useful in a wide range of applications including wound treatment, as a medical diagnostic comprising a particulate support and a functional material bound or retained by the support and solid phase synthesis of peptides, oligonucleotides, oligosaccharides, immobilisation of species, cell culturing and in chromatographic separation. | 2014-05-22 |
20140142199 | ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES - The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile. | 2014-05-22 |
20140142200 | Keratoprosthesis - The invention comprises a method of making molded, double-crosslinked (i.e., two stages of crosslinking), transparent, collagen materials using a novel combination of diafiltration, lyophilization, and homogenization. The collagen material can be used not only as an ophthalmic device, but also as a tissue scaffold, drug delivery device, wound dressing, or other collagen hydrogel based device. | 2014-05-22 |
20140142201 | STEVIA COMPOSITION - compositions are prepared from steviol glycosides of | 2014-05-22 |
20140142202 | STRUCTURED AQUEOUS SURFACTANT SYSTEMS - The invention provides a structured aqueous surfactant system comprising: a) at least 0.1 wt % nonionic surfactant which is a polyoxyethylene nonionic surfactant having a hydrophilic head group with at least four oxyethylene units; b) from 0.5 to 5 wt % dispersed modified cellulose biopolymer, wherein the modification consists of the cellulose having its C6 primary alcohols oxidised to carboxyl moieties (acid/COOH—) on 10 to 70% of the glucose units and substantially all the remainder of the C6 positions occupied by unmodified primary alcohols; c) from 0 to 10 wt % non-surfactant electrolyte, and d) water. | 2014-05-22 |
20140142203 | COSMETIC COMPOSITION - Provided is a cosmetic composition which has a structure-recovering property, is transparent, is excellent in thermal stability, is satisfactory in smoothness when applied to the skin or hair, and has a good feeling in use, and which comprises components (A) to (D) as described. | 2014-05-22 |
20140142204 | PROCESS AND SYSTEM FOR BLENDING SYNTHETIC AND NATURAL CRUDE OILS AND BLENDS MADE THEREBY. - A process and system are described for producing a synthetic crude oil by contacting a synthesis gas with a combination of a synthesis gas conversion catalyst and a hydroconversion catalyst in a synthesis gas reactor. The synthesis gas can be obtained from gas associated with crude oil production, i.e., associated gas, in a synthesis gas generator. The synthetic crude oil can be blended with a natural crude oil to produce a blended stabilized crude oil having 2 wt % or more of the synthetic crude oil. The resulting blended stabilized crude oil has improved flow characteristics including a pour point of 30° C. or less. | 2014-05-22 |
20140142205 | Fischer-Tropsch Process for Producing Hydrocarbons from Biogas - A Fischer-Tropsch process for producing hydrocarbons from synthesis gas which originates e.g. from biomass gasification, using membrane separators. In the process, an input stream which comprises hydrogen, carbon monoxide as well as further gases and/or vapours is initially fed to a first membrane stage which comprises a steam-selective and carbon dioxide-selective membrane and through which at least some of the steam present in the input stream and some of the carbon dioxide present in the input stream are separated from the input stream to form a permeate stream of the first membrane stage comprising steam and carbon dioxide and a retentate stream of the first membrane stage containing hydrogen and carbon monoxide. | 2014-05-22 |
20140142206 | CARBON SUPPORTED COBALT AND MOLYBDENUM CATALYST AND USE THEREOF FOR PRODUCING LOWER ALCOHOLS - The present invention relates to a method for preparing a catalyst composition comprising cobalt and molybdenum on a carbon support, characterized in that the cobalt- and molybdenum-source are dissolved in an organic solvent that is miscible with water. Moreover, a carbon supported cobalt molybdenum catalyst composition obtainable by said method and a process for producing alcohols from syngas using said carbon supported cobalt molybdenum catalyst composition is provided. | 2014-05-22 |
20140142207 | ULTRA LOW DENSITY BIODEGRADABLE SHAPE MEMORY POLYMER FOAMS WITH TUNABLE PHYSICAL PROPERTIES - Compositions and/or structures of degradable shape memory polymers (SMPs) ranging in form from neat/unfoamed to ultra low density materials of down to 0.005 g/cc density. These materials show controllable degradation rate, actuation temperature and breadth of transitions along with high modulus and excellent shape memory behavior. A method of making extremely low density foams (up to 0.005 g/cc) via use of combined chemical and physical blowing agents, where the physical blowing agents may be a single compound or mixtures of two or more compounds, and other related methods, including of using multiple co-blowing agents of successively higher boiling points in order to achieve a large range of densities for a fixed net chemical composition. Methods of optimization of the physical properties of the foams such as porosity, cell size and distribution, cell openness etc. of these materials, to further expand their uses and improve their performance. | 2014-05-22 |
20140142208 | FOAMING COMPOSITION FOR FILLING, FOAMING MEMBER FOR FILLING, AND FOAM FOR FILLING - A foaming composition for filling contains a polymer, an organic peroxide, and azodicarbonamide, and a viscosity thereof measured at a temperature of 120° C. and under a pressure of 500 MPa with a flow tester is in a range of 1050 to 4950 Pa·s. | 2014-05-22 |
20140142209 | FLUOROPOLYMER, PRODUCTION METHOD FOR FLUOROPOLYMER, AND POROUS POLYMER FILM - A fluoropolymer including a vinylidene fluoride unit, a tetrafluoroethylene unit, and a unit represented by the following formula ( | 2014-05-22 |
20140142210 | ADHESIVE COMPOSITION - The present invention relates to an adhesive composition, which comprises, based on the total weight of the adhesive composition: | 2014-05-22 |